<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-87 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-87</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-87</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <p><strong>Paper ID:</strong> paper-6e2ee765733b0bb37f89e220076a56afd3176c3b</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/6e2ee765733b0bb37f89e220076a56afd3176c3b" target="_blank">Lung cancer: Biology and treatment options.</a></p>
                <p><strong>Paper Venue:</strong> Biochimica et Biophysica Acta</p>
                <p><strong>Paper TL;DR:</strong> The purpose of this review is to summarize the recent developments in lung cancer biology and its therapeutic strategies, and discuss the latest treatment advances including therapies currently under clinical investigation.</p>
                <p><strong>Cost:</strong> 0.025</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e87.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e87.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Smoking history / exposure</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette smoking history and exposure metrics (qualitative)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Paper-wide descriptor of smoking as primary lung cancer cause and grouping variable (never, former/light, current smokers, long-term history), used to stratify molecular and clinical differences but typically presented qualitatively rather than by precise pack‑years in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / summary of clinical and molecular studies</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>General lung cancer patient populations discussed across studies; comparisons repeatedly made between never-smokers, former/light smokers, and smokers; some ethnicity-specific notes (East Asian vs Caucasian).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Qualitative categories used in the paper: never-smokers, former light-smokers, current smokers, >20 years smoking history; no consistent pack‑years, cotinine, or biomarker-verified exposure metrics reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>General outcomes discussed (incidence, histologic subtype, stage, survival, treatment response); ascertainment methods vary by cited studies (pathology-confirmed tumors and clinical trials) but not standardized in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Socioeconomic status and access to care (discussed as affecting survival and observed racial disparities; can confound observed smoker-subgroup outcomes).']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Descriptive epidemiology: ~90% of lung cancer cases caused by smoking; authors note incidence and mortality patterns are consistently associated with ≥20 years of smoking history; comparisons in trials often stratify by never/former-light vs smokers (numerical values provided in specific biomarker/treatment entries).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Differences in internal dose, metabolic activation/detoxification of procarcinogens, DNA adduct formation, DNA repair capacity, host genetics, and tumor/immune microenvironment are all invoked as reasons why only some smokers develop lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Review emphasizes heterogeneous exposure measurement across studies (qualitative smoking categories common), making cross-study comparison and quantification of dose–response among smokers difficult.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e87.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor activating mutations (EGFR)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic activating EGFR mutations occur in a subset of NSCLC (especially adenocarcinoma), are enriched in never-smokers and East Asian patients, and strongly predict response to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular epidemiology / clinical trial subgroup observations summarized</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patients (adenocarcinoma-enriched); paper cites prevalence ~10% in US NSCLC and ~35% in East Asian NSCLC; enriched in never-smokers and women.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Categorical: never-smokers and former/light smokers are specifically noted as the groups with higher EGFR mutation frequency and greater benefit from EGFR TKIs; no pack‑year cutoffs provided.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor EGFR mutation status (molecular assay); clinical outcomes discussed include progression-free survival (PFS) and overall survival (OS) on EGFR TKI therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene': 'EGFR', 'variant_identifier': None, 'direction_of_effect': 'Activating EGFR mutations → increased sensitivity to EGFR TKIs and improved PFS on targeted therapy.', 'association_context': 'Enriched in never-smokers and East Asian ancestry; predictive of TKI response rather than increased susceptibility per se in smokers.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': ['EGFR'], 'environmental_factor': 'Smoking status (never vs ever)', 'interaction_model': 'qualitative (enrichment rather than formal interaction model reported)', 'summary': 'EGFR activating mutations are far more common in never-smokers/never-or-light smokers; this stratification underlies differential therapeutic response to EGFR TKIs between never-smokers and smokers.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>['EGFR activation is reported to upregulate PD-L1 expression (immune-evasion link).']</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['EGFR-mutant tumors: enriched in never-smokers, distinct from smoking-associated mutational patterns.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>EGFR mutation prevalence: ~10% in US NSCLC vs ~35% in East Asian NSCLC; EGFR-mutant patients derive larger PFS benefit from EGFR TKIs in trials of nonsmokers/former light smokers (examples in the review: PFS improvements versus chemotherapy; specific trial numbers given elsewhere in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>EGFR-mutant tumors represent a molecularly distinct subset less linked to tobacco mutagenesis; therefore among smokers (and especially never-smokers) tumor-driving events differ, which partly explains heterogeneity in who develops lung cancer and in treatment response.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>EGFR associations are observational and strongly confounded by smoking status and ethnicity; effect sizes reported are from clinical trials enriched for EGFR-mutant disease rather than population-level susceptibility estimates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e87.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion oncogene</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A somatic chromosomal rearrangement forming an EML4–ALK fusion occurs in ~4% of NSCLC and is typically found in never- or light-smokers; tumors harboring the fusion are sensitive to ALK inhibitor crizotinib but resistance emerges via secondary ALK mutations or alternative signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular epidemiology / clinical trial observations</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patients (adenocarcinoma predominant), fusion found in ~4% of NSCLC, enriched in never or former light smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Categorical: more common in never- or former light smokers; no quantitative exposure metrics provided.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>EML4-ALK positive status by molecular testing; clinical outcomes include response to crizotinib and survival.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene': 'EML4-ALK fusion', 'variant_identifier': None, 'direction_of_effect': 'Presence → sensitivity to ALK inhibitor (crizotinib); associated with lack of response to EGFR TKIs.', 'association_context': 'Enriched in never/light smokers; largely mutually exclusive with EGFR and KRAS mutations.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': ['EML4-ALK'], 'environmental_factor': 'Smoking status', 'interaction_model': 'qualitative', 'summary': 'EML4-ALK fusions are concentrated in never- or light-smoker subgroups, demonstrating a gene×smoking-status stratification in tumor etiology and therapeutic sensitivity.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['EML4-ALK tumors typically lack canonical tobacco-associated driver mutations and are enriched in never/light smokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Prevalence ~4% overall; EML4-ALK positivity predicts crizotinib sensitivity; resistance mechanisms include ALK kinase domain mutations (e.g., L1196M, C1156Y) and bypass signaling (EGFR, KRAS noted as potential co-alterations in a minority).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>ALK fusion tumors arise via oncogenic rearrangements more common in never/light smokers, indicating alternative carcinogenic pathways independent of heavy tobacco mutagenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Percentages from clinical series; enrichment in never/light smokers may reflect sampling and histology (adenocarcinoma) biases.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e87.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS oncogenic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS mutations are recurrent driver alterations in NSCLC (more common in smokers and in Caucasian populations) and are associated with poorer response to EGFR-targeted therapies and distinct immune marker patterns.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular epidemiology summary</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patients; KRAS prevalence ~18% overall, noted to be lower (<10%) in East Asian patients; associated clinical profiles include male smokers with adenocarcinoma in some datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Associations are described with smoking status (higher prevalence in smokers), but no quantitative exposure (pack‑years) is provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor KRAS mutation status by sequencing; outcomes referenced include treatment resistance (EGFR TKI and crizotinib contexts) and immune marker expression.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene': 'KRAS', 'variant_identifier': None, 'direction_of_effect': 'KRAS mutations → negative prognostic indicator for maintenance erlotinib PFS and may confer resistance to some targeted therapies.', 'association_context': 'More frequent in smokers and in non-Asian populations; associated with higher PD-1 expression.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': ['KRAS'], 'environmental_factor': 'Smoking status', 'interaction_model': 'qualitative', 'summary': 'KRAS mutations are linked with smoking-associated tumors and are associated with distinct immune microenvironment features (e.g., higher PD-1).'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>['KRAS-mutant tumors show higher PD-1 expression (immune microenvironment difference).']</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['KRAS mutations are characteristic of tobacco-associated mutational patterns and are more common in smokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>KRAS prevalence ~18% in some populations vs <10% in East Asians; KRAS mutation status identified as a negative prognostic factor for maintenance erlotinib-induced PFS in one trial context.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>KRAS-driven tumors reflect carcinogenic processes linked to tobacco mutagens; KRAS mutations reshape tumor biology and immune interactions, contributing to heterogeneity in which smokers develop lung cancer and to differential therapy responses.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Cross-population prevalence differences confounded by ancestry and smoking patterns; specific variant-level risk estimates are not provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e87.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tumor mutational burden (TMB) / neoantigen burden</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Nonsynonymous tumor mutation burden and neoantigen load (molecular smoking signature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Higher nonsynonymous somatic mutation burden (and a molecular smoking signature) correlates with better objective response, durable clinical benefit, and PFS on anti-PD-1 therapy; this links higher tobacco-associated mutational load to differential immunotherapy responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular biomarker correlation (whole-exome sequencing cohorts cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Two independent NSCLC cohorts treated with anti–PD-1 therapy analyzed by whole-exome sequencing; cohorts include different histologies but not fully detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Molecular smoking signature (from tumor sequencing) used rather than self-reported pack‑years; signature correlates with smoking history.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Objective response rate (ORR), durable clinical benefit, and progression-free survival (PFS) after anti–PD-1 therapy (pembrolizumab) measured; tumor sequencing used to derive nonsynonymous mutation counts.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': [], 'environmental_factor': 'Tobacco exposure measured via molecular smoking signature', 'interaction_model': 'statistical correlation (biomarker-response association)', 'summary': 'Tumors with molecular signatures of tobacco exposure and higher nonsynonymous mutation burden showed improved response to anti–PD-1 therapy, implying that smoking-induced mutational load can modify immune-checkpoint therapy efficacy.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>['Mutations in DNA repair and replication pathway genes (POLD1, POLE, MSH2, Rad51, Rad17, DNA-PK) were associated with pembrolizumab clinical efficacy.']</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['Higher TMB and neoantigen burden characteristic of tumors with tobacco mutation signature (smoking-associated).']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Higher nonsynonymous mutation burden associated with improved ORR, durable benefit, and PFS on anti–PD-1 therapy in the cohorts analyzed (paper does not provide pooled numeric effect sizes within the review text). Mean somatic mutation rate in one dataset: 8.87 mutations/megabase (LUAD sequencing study).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td>Reported correlation between TMB and response to PD-1 blockade; no explicit AUC/c-statistic provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Smoking increases somatic mutations → higher neoantigen load → greater immunogenicity and potential responsiveness to immune checkpoint blockade in those tumors, partially explaining heterogeneity among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Analyses relate to treated cohorts (immunotherapy), not population-level susceptibility to developing cancer; TMB is tumor-derived, so it cannot prospectively identify which smokers will develop cancer without tumor sampling.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e87.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ERCC1 and DNA repair</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERCC1 expression and other DNA repair / replication pathway genes</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ERCC1 expression level is discussed as a predictor of platinum chemotherapy sensitivity (low ERCC1 → increased sensitivity); mutations in DNA repair and replication genes (e.g., POLD1, POLE, MSH2, Rad51, Rad17, DNA-PK) are linked to immunotherapy efficacy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>biomarker / predictive marker discussion</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC tumor cohorts and clinical trial populations; ERCC1 expression prevalence: nearly 50% of NSCLC have low ERCC1 expression.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not specifically stratified by smoking status in the review text for ERCC1; discussed as tumor biomarker influencing therapy response.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Therapy response (platinum sensitivity), overall prognosis; assays for ERCC1 protein or mRNA levels implied.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene': 'ERCC1', 'variant_identifier': None, 'direction_of_effect': 'Low ERCC1 expression → increased sensitivity to platinum-based chemotherapy; high ERCC1 → better overall prognosis but lower platinum sensitivity.', 'association_context': 'Therapy-predictive biomarker in NSCLC tumors; prevalence ~50% low ERCC1.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>['ERCC1 expression level (NER pathway) discussed; mutations in DNA repair/replication genes (POLD1, POLE, MSH2, Rad51, Rad17, DNA-PK) associated with immunotherapy response.']</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Nearly 50% of NSCLC patients have low ERCC1; low ERCC1 correlates with increased platinum sensitivity (no numeric HR/OR given in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Variability in DNA repair capacity (e.g., ERCC1-mediated NER) alters how tobacco-induced DNA lesions are repaired, influencing cancer risk and treatment sensitivity.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>ERCC1 predictive value derived from tumor analyses and treatment cohorts; not directly established here as a prospective risk marker among healthy smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e87.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Carcinogen activation/detoxification & DNA adducts</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Host metabolic activation/detoxification pathways and DNA adduct formation (general)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Review states that inter-individual susceptibility depends on gene–enzyme interactions that alter activation/detoxification of procarcinogens and on levels of DNA adduct formation, but does not enumerate specific variants in detail.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>conceptual/mechanistic (reviewed concept)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>General statement applicable to smokers; no specific cohort detailed in the review for these markers.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not quantified; concept links internal dose/metabolism to the same external exposure producing variable internal carcinogen dose.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Not specified for a single study—conceptual link to incidence through DNA adduct burden.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene': None, 'variant_identifier': None, 'direction_of_effect': None, 'association_context': 'Review mentions metabolic activation/detoxification genes conceptually (e.g., CYPs, GSTs), but no specific gene-level associations or rsIDs are provided in the text.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': [], 'environmental_factor': 'Tobacco carcinogen exposure', 'interaction_model': 'conceptual (metabolic gene variants modify internal dose from external smoking exposure)', 'summary': 'Inter-individual variation in enzymes that activate/detoxify tobacco carcinogens will alter DNA adduct formation and thus modulate lung cancer susceptibility among smokers; specific examples are not enumerated in the review.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[{'marker': 'DNA adducts (general)', 'tissue': 'lung tissue (conceptually) or exposed airway epithelium', 'relationship_to_risk': 'Higher DNA adduct levels are proposed to increase risk; specific quantitative relationships not provided in the review.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>No numeric effect sizes provided for metabolic gene variants or DNA adduct burden in this review—conceptual statement only.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Variation in activation/detoxification enzymes leads to differences in formation and persistence of DNA adducts from tobacco carcinogens, affecting the probability of malignant transformation among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Review does not provide study-level data; specific genes/variants and biomarker assay standardization are not detailed, limiting quantitative interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e87.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Epigenetic marker: SULF2 methylation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SULF2 promoter methylation / expression</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>SULF2, a heparan sulfate 6-O-endosulfatase, is overexpressed in many lung tumors; SULF2 methylation (reduced expression) has been associated with better survival and increased sensitivity to topoisomerase‑1 inhibitors in NSCLC.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>biomarker association (epigenetic) discussed in review</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC tumor cohorts (subtype details not exhaustively provided); association with methylation status and drug sensitivity reported in referenced studies.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not stratified by smoking within the review's description of SULF2 findings.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Overall survival and drug sensitivity (in vitro and/or clinical correlation implied); methylation status determined in tumor tissue.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>['SULF2 methylation in tumor tissue → associated with better survival and increased sensitivity to topoisomerase‑1 inhibitors; mechanism involves induction of ISG15 and altered ubiquitin-proteasome degradation.']</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review reports association (directional) but does not provide numeric effect sizes for SULF2 methylation on survival within the text.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Epigenetic silencing of SULF2 reduces release of growth factors from HSPGs and induces ISG15 expression, sensitizing tumors to topoisomerase inhibitors and correlating with better outcomes — illustrating how epigenetic differences in tumors can stratify risk and therapy response.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Findings relate to tumor phenotype (post-diagnosis) and are not presented as prospective markers of which smokers will develop cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e87.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tumor immune microenvironment / chronic inflammation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor microenvironment immune composition and chronic inflammation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review details heterogeneous immune and inflammatory states (TAM M1/M2 balance, MDSC, Tregs, DC maturation, Ti-BALT) that vary between patients and influence tumor progression, prognosis, and potentially which smokers develop lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review of tumor microenvironment studies</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patient tumors at various stages; immune subset densities and tertiary lymphoid structures examined in small clinical/retrospective cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not consistently reported in relation to microenvironment features in the review (associations may exist but not detailed).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Disease-free survival, disease-specific survival, and overall survival correlated with intratumoral immune features (e.g., DC-LAMP+ density, Ti-BALT presence).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>['Chronic inflammation and infection described as contributors to carcinogenesis via ROS/RNS release and NF-κB activation; tertiary lymphoid structures (Ti-BALT) in early-stage NSCLC correlate with improved outcomes.']</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['Immune cell subset composition varies considerably among patients and may correlate with histology and likely with exposure history (not fully detailed).']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Presence of mature DCs in Ti-BALT correlated with improved disease-free and overall survival in a small retrospective study (no numeric HRs provided in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Differences in immune surveillance and chronic inflammation alter the probability that tobacco‑mutagenized cells progress to malignancy; immunosuppressive microenvironments (MDSC, M2 TAMs, Tregs) favor tumor development in some smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Most microenvironment observations are from tumor tissue post-diagnosis; causality and prospective predictive value for at-risk smokers are not established in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e87.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Race / ethnicity and SES</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Racial/ethnic differences and socioeconomic modifiers</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review documents racial and ethnic disparities in incidence, mutation prevalence (EGFR more frequent in East Asians, KRAS less frequent), and notes socioeconomic factors (access to care, treatment receipt) that alter observed lung cancer risk and outcomes among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiologic observations / review</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Population-level incidence and clinical-trial subgroup observations: African-American men have highest incidence/mortality in US; East Asian patients have higher EGFR mutation frequency and better response to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Smoking history referenced qualitatively; differences in mutation prevalence and outcomes discussed stratified by ethnicity and smoking status (e.g., never-smoker adenocarcinoma enrichment).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Incidence and mortality statistics by race/ethnicity; trial-derived OS/PFS differences by ethnicity and molecular status.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': [], 'environmental_factor': 'Ethnicity and smoking interactions', 'interaction_model': 'observational stratification', 'summary': 'Ethnicity modifies prevalence of actionable mutations (EGFR, KRAS) and thus modifies how smoking history translates into lung cancer risk and treatment outcomes.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Access to care, insurance, adherence to treatment; these non-biological modifiers are described as contributing to survival disparities and may confound observed associations between smoking and risk/outcome.']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['EGFR mutation frequency 30% in East Asian patients vs 7% in Caucasian patients (as reported); KRAS prevalence lower in Asians (<10%) vs ~18% overall.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>EGFR mutation frequency: ~30% East Asia vs ~7% Caucasians (review reports ~35% vs 10% in other loci); KRAS prevalence <10% in Asians vs 18% in other groups.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Genetic background and environmental/contextual factors (including healthcare access) alter the effective risk among smokers and observed outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Potential confounding by differential screening, treatment access, and study enrollment across racial/ethnic groups.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e87.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e87.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-1 / PD-L1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Programmed cell death protein 1 (PD-1) and its ligand PD-L1 expression</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PD-1/PD-L1 expression in tumors and immune cells varies across molecular subgroups (higher PD-1 with KRAS mutations; increased PD-L1 with EGFR mutations/ALK translocations) and PD-L1 expression correlates with objective response to PD-1 blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>biomarker–therapy response correlations (clinical trials and phase I/II studies summarized)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patients in early-phase anti–PD-1/PD-L1 trials and larger randomized trials (e.g., CheckMate-017/057) spanning squamous and nonsquamous histologies.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Associations described with smoking-related molecular profiles (KRAS-linked PD-1, EGFR-linked PD-L1) rather than direct pack‑year measures.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Objective response rate (ORR), durable clinical benefit, PFS, OS in immunotherapy trials; PD-L1 tumor expression assessed by immunohistochemistry in trial cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'genes': ['EGFR', 'KRAS', 'ALK'], 'environmental_factor': 'Smoking-associated tumor biology', 'interaction_model': 'observational correlation', 'summary': 'Genomic alterations linked to smoking status correlate with PD-1/PD-L1 expression: KRAS mutant tumors (smoking-associated) show higher PD-1; EGFR/ALK-altered tumors show higher PD-L1.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>['PD-L1 tumor expression (IHC) is used as a predictive marker for benefit from PD-1/PD-L1 blockade.']</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['PD-1/PD-L1 expression profiles differ across mutation-defined subgroups that associate with smoking history.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Anti–PD-1 (nivolumab) produced durable objective responses in ~18% of NSCLC patients in early studies; CheckMate-017 showed a 41% OS improvement with nivolumab vs docetaxel in squamous NSCLC, and CheckMate-057 a 27% OS improvement in nonsquamous NSCLC. PD-L1 expression correlated with objective response (P=0.025).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td>PD-L1 tumor expression correlated significantly with objective response and clinical benefit in early anti–PD-1 studies; no pooled AUC reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Tumor genomic changes induced/selected by tobacco alter immune-checkpoint ligand expression, modulating immune evasion and thus differential progression risk and treatment response among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>PD-L1 assays and thresholds vary across trials; expression in immune cells vs tumor cells had different correlation strengths; smoking status associations are indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung cancer: Biology and treatment options.', 'publication_date_yy_mm': '2015-12'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <p class="empty-note">No potentially relevant new papers extracted.</p>
        </div>

        </div>

    </div>
</body>
</html>